SCHEMBL5379812

SCHEMBL5379812

O=C(O)c1cccc(-c2ccnc(Nc3ccccc3)n2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.77
PRKCA P17252 4/20 0.77
BCR P11274 4/20 0.77
CAMK2D Q13557 5/20 0.76
MAPK8 P45983 3/20 0.73
PIK3CG P48736 2/20 0.73
GSK3B P49841 2/20 0.73
CAMKK2 Q96RR4 2/20 0.73
MAPK10 P53779 1/20 0.64
PRKCD Q05655 3/20 0.64
EGFR P00533 1/20 0.64
SRC P12931 3/20 0.64
PDGFRB P09619 2/20 0.64
PDGFRA P16234 2/20 0.64
PRKD3 O94806 1/20 0.64
PRKCG P05129 1/20 0.64
PRKCB P05771 1/20 0.64
PRKCH P24723 1/20 0.64
PRKCI P41743 1/20 0.64
PRKCE Q02156 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25337094 0.88 ABL1 (0.75) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL31118910 0.88 ABL1 (0.75) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL1655099 0.87 ABL1 (1.00) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL27115954 0.87 ABL1 (0.74) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL4902223 0.86 ABL1 (0.80) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL4376512 0.86 PLK1 (0.72) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL4897053 0.85 ABL1 (0.71) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL3758823 0.85 MAPK8 (0.76) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL7463871 0.84 ABL1 (0.70) ABL1PRKCABCRCAMK2DMAPK8
SCHEMBL31119008 0.84 PLK1 (0.74) ABL1PRKCABCRCAMK2DMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304071-B2 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-04 US disclosed
CN-1863780-A Protein kinase inhibitor and application thereof VERTEX PHARMA (US) 2006-11-15 CN disclosed
EP-1546117-A2 PROTEIN KINASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2005-06-29 EP disclosed
US-20040106615-A1 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-06-03 US disclosed
WO-2004016597-A2 PROTEIN KINASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106615-A1 Protein kinase inhibitors and uses thereof JAK1, RAF1, PRKCQ ABL1 367/4885PRKCA 14/4885BCR 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.